Lilly Responds to Verdict in Case of Terrence Allen, et al. v. Takeda

INDIANAPOLIS, April 24, 2014 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY)
issued the following statement today in response to the verdict in the case of
Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al. No.
6:12-cv-00064. The jury found in favor of the plaintiffs and awarded $1.475
million in compensatory damages. The allocation of liability was 75% Takeda and
25% Lilly. The jury also awarded $6 billion in punitive damages from Takeda and
$3 billion from co-defendant, Lilly.

“While we have empathy for the plaintiff, we believe the evidence did not
support his claims,” said Mike Harrington, Senior Vice President and General
Counsel. “Lilly disagrees with the verdict and we intend to vigorously challenge
this outcome through all available legal means.”

Judgments were entered in Takeda’s favor in all three previous Actos trials.
Lilly was not named previously. This is the first federal case to be tried and
the first in the consolidated Actos multidistrict litigation (MDL). Lilly
copromoted Actos with Takeda from 1999 to 2006.

Under Lilly’s agreement with Takeda, Lilly will be indemnified by Takeda for its
losses and expenses with respect to the U.S. litigation and other related
expenses in accordance with the terms of its indemnification agreement.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make
life better for people around the world. We were founded more than a century ago
by a man committed to creating high-quality medicines that meet real needs, and
today we remain true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to those who need
them, improve the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more about Lilly,
please visit us at and


This press release contains forward-looking statements relating to Actos product
liability litigation. There can be no guarantees of the outcome of the
litigation or the related indemnification agreement. For these and other risks
affecting the company, please see the company’s most recent report on Form 10-K
filed with the U.S. Securities and Exchange Commission. Except as required by
law, Lilly undertakes no duty to update forward-looking statements.

Refer to: Kelley Murphy, 317-701-4007

Logo –

SOURCE Eli Lilly and Company

Leave a Reply

Fatal error: Call to undefined function show_subscription_checkbox() in /home3/steer/public_html/ on line 95